What is the recommended protocol for Venofer (iron sucrose) infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Venofer (Iron Sucrose) Infusion Protocol

Venofer must only be administered intravenously either by slow injection or by infusion, with the dosage expressed in mg of elemental iron (20 mg/mL). 1

Administration Methods

Direct IV Injection (Slow IV Push)

  • Administer undiluted at a rate of 100 mg over 2-5 minutes 1
  • This method is more convenient than longer infusions and is licensed for use 2

IV Infusion

  • For 100 mg dose: Dilute in maximum 100 mL of 0.9% NaCl and infuse over at least 15 minutes 1
  • For 200 mg dose: Dilute in maximum 100 mL of 0.9% NaCl and infuse over 15 minutes 1
  • For 300-500 mg doses: Dilute in maximum 250 mL of 0.9% NaCl 1, 3

Dosing by Patient Population

Hemodialysis-Dependent CKD (HDD-CKD)

  • Administer 100 mg per consecutive hemodialysis session, early during dialysis (generally within first hour) 1
  • Usual total treatment course is 1000 mg 1
  • Treatment may be repeated if iron deficiency recurs 1

Non-Dialysis Dependent CKD (NDD-CKD)

  • Option 1: 200 mg on 5 different occasions over a 14-day period (total 1000 mg) 1
  • Option 2: 500 mg on Day 1 and Day 14 (total 1000 mg), infused over 3.5-4 hours 1

Peritoneal Dialysis Dependent CKD (PDD-CKD)

  • Administer in 3 divided doses within a 28-day period: 1
    • Two infusions of 300 mg over 1.5 hours, 14 days apart
    • One infusion of 400 mg over 2.5 hours, 14 days after second dose

Pediatric Patients (2 years and older)

  • For maintenance: 0.5 mg/kg (not exceeding 100 mg per dose) 1
  • For HDD-CKD: Every two weeks for 12 weeks 1
  • For NDD-CKD or PDD-CKD: Every four weeks for 12 weeks 1

Safety Considerations

Maximum Dosing

  • Maximum single dose: 200 mg 3
  • Maximum weekly dose: 500 mg 3
  • Typical administration is 100 mg per dose to minimize risk of adverse effects 4

Monitoring

  • Monitor vital signs during and after infusion 2
  • Follow hemoglobin, ferritin, and transferrin saturation levels to assess response to therapy 4, 5
  • Free iron may occur if 100 mg is administered when transferrin levels are less than 180 mg/dL 4

Potential Adverse Effects

  • Hypotension and flushing (rare) 4, 5
  • Abdominal cramps (rare, particularly when co-administered with ACE inhibitors) 4, 5
  • Arthralgias and myalgias (acute rather than delayed) 4, 5
  • These adverse effects are dose-related and rarely occur with doses of 100 mg or less 4

Clinical Efficacy

  • Iron sucrose has been shown to effectively maintain hemoglobin levels in hemodialysis patients 6, 7
  • IV iron sucrose is more effective both clinically and financially than oral iron preparations in hemodialysis patients 8
  • When combined with low-dose erythropoietin, iron sucrose shows rapid improvement in anemia correction in predialysis CKD patients 9

Important Precautions

  • Anaphylaxis may occur with IV iron preparations, so resuscitation facilities should be available during administration 2
  • Patients with active infection should not receive IV iron therapy 3
  • Test doses are not required for iron sucrose (unlike iron dextran), but are recommended for patients with history of sensitivities to IV iron preparations or multiple drug allergies 3

References

Guideline

Administration of Iron Sucrose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Iron Sucrose Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Dark-Colored Urine Following Iron Sucrose Infusion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015

Research

A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.